209 related articles for article (PubMed ID: 38326829)
1. MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways.
Verma VK; Beevi SS; Nair RA; Kumar A; Kiran R; Alexander LE; Dinesh Kumar L
Cell Commun Signal; 2024 Feb; 22(1):100. PubMed ID: 38326829
[TBL] [Abstract][Full Text] [Related]
2. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
3. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum.
Chen X; Li X; Wang J; Zhao L; Peng X; Zhang C; Liu K; Huang G; Lai Y
Biomark Med; 2021 Aug; 15(12):951-963. PubMed ID: 34293926
[No Abstract] [Full Text] [Related]
4. Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.
Swellam M; El Magdoub HM; Hassan NM; Hefny MM; Sobeih ME
Clin Biochem; 2018 Jun; 56():47-54. PubMed ID: 29679553
[TBL] [Abstract][Full Text] [Related]
5. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
6. miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma.
Lu N; Zhang M; Lu L; Liu YZ; Zhang HH; Liu XD
Oncol Rep; 2021 Feb; 45(2):706-716. PubMed ID: 33416185
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA analysis of breast ductal fluid in breast cancer patients.
Do Canto LM; Marian C; Willey S; Sidawy M; Da Cunha PA; Rone JD; Li X; Gusev Y; Haddad BR
Int J Oncol; 2016 May; 48(5):2071-8. PubMed ID: 26984519
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the miR-637 and miR-523-5p as candidate biomarkers in breast cancer.
Coskunpinar E; Tiryakioglu DZ; Abaci N; Tukenmez M; Pence S
Bratisl Lek Listy; 2023; 124(11):814-820. PubMed ID: 37874803
[TBL] [Abstract][Full Text] [Related]
9. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
10. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
He H; Di Y; Liang M; Yang F; Yao L; Hao S; Li J; Jiang Y; Jin C; Fu D
Oncol Rep; 2013 Aug; 30(2):651-8. PubMed ID: 23733161
[TBL] [Abstract][Full Text] [Related]
11. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.
Volinia S; Croce CM
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7413-7. PubMed ID: 23589849
[TBL] [Abstract][Full Text] [Related]
12. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
[TBL] [Abstract][Full Text] [Related]
13. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
14. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
[TBL] [Abstract][Full Text] [Related]
16. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
[TBL] [Abstract][Full Text] [Related]
17. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
18. Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2019 May; 189(5):966-974. PubMed ID: 30273605
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
[TBL] [Abstract][Full Text] [Related]
20. Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
Li Z; Peng Z; Gu S; Zheng J; Feng D; Qin Q; He J
Anticancer Res; 2017 Aug; 37(8):4455-4468. PubMed ID: 28739740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
